Cargando…

A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system

SummaryAn automated cartridge-based detection system (GeneXpert; Cepheid) is being widely adopted in low throughput laboratories for monitoring BCR-ABL1 transcript in chronic myelogenous leukaemia. This Australian study evaluated the longitudinal performance specific characteristics of the automated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enjeti, Anoop, Granter, Neil, Ashraf, Asma, Fletcher, Linda, Branford, Susan, Rowlings, Philip, Dooley, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Haematology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699369/ https://www.ncbi.nlm.nih.gov/pubmed/26166664 http://dx.doi.org/10.1097/PAT.0000000000000293

Ejemplares similares

Expansion of BCR/ABL1 (+) cells requires PAK2 but not PAK1
por: Edlinger, Leo, et al.
Publicado: (2017)

BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique
por: Branford, Susan
Publicado: (2022)

Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia
por: Branford, Susan
Publicado: (2022)

Cup‐like blasts in an adult patient with BCR‐ABL1 positive B‐cell acute lymphoblastic leukemia
por: Wang, Zhenni, et al.
Publicado: (2022)

Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCR‐ABL1 detection failure using RT‐MLPA (positive RT‐qPCR)
por: Coster, Lucie, et al.
Publicado: (2021)

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale
por: Yoshida, Chikashi, et al.
Publicado: (2016)

Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR–ABL1 on the international reporting scale
por: Brown, J T, et al.
Publicado: (2011)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow
por: Berry, Nadine Kaye, et al.
Publicado: (2014)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
por: Pagani, Ilaria S., et al.
Publicado: (2018)

P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES
por: Lang, Fabian, et al.
Publicado: (2023)

A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia
por: Enjeti, Anoop K., et al.
Publicado: (2016)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
por: Parker, W T, et al.
Publicado: (2013)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study
por: Roshani, Sara, et al.
Publicado: (2011)

High body mass index in children with sickle cell disease: a retrospective single-centre audit
por: Hall, Rachael, et al.
Publicado: (2018)

Comparison of pulse oximetry and earlobe blood gas with CO-oximetry in children with sickle cell disease: a retrospective review
por: Arigliani, Michele, et al.
Publicado: (2020)

Paediatric sickle cell disease at a tertiary hospital in Malawi: a retrospective cross-sectional study
por: Chimbatata, Chikondi Sharon, et al.
Publicado: (2021)

B-cell hepatosplenic lymphoma presenting in adult patient after spontaneous splenic rupture followed by severe persistent hypoglycaemia: type B lactic acidosis and acute liver failure
por: Moen, Mette, et al.
Publicado: (2023)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing
por: Lee, Hyeonah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iljtc4fvnrvb77tfmrj37kbbc0